SARS-CoV-2 is a novel emerged positive-strand RNA virus associated with an acute respiratory distress disease known as COVID-19. Studies have suggested that transmission of SARS-CoV-2 is primarily from person to person through respiratory droplets ([@B1],[@B2]). In addition, there is emergent evidence that the virus could be detected in biological fluids including bronchoalveolar lavage fluid specimens ([@B3]), blood ([@B3],[@B4]) and saliva ([@B5]), but substantial knowledge gaps remain regarding the presence of SARS-CoV-2 in the breast milk. Recently, a report in *Science* discussed the wrenching choices of pregnant women with COVID-19 after childbirth including whether or not they should breastfeed their children ([@B6]).

METHODS
=======

We performed a rapid systematic review to evaluate the current evidence related to the presence of SARS-CoV-2 in breast milk from pregnant women with COVID-19. The study was conducted in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines ([@B7]), but given emergency-need for this review, PROSPERO registration was not sought. Using terms related to coronavirus, we searched in PubMed, Web of Science, Scopus, China National Knowledge Infrastructure database, and grey literature (Google Scholar and preprint repositories) to identify studies reporting results of RT-PCR tests on breast milk in pregnant women with laboratory-confirmed SARS-CoV-2 infection. Searches were performed up to March 30, 2020 and updated on April 21, 2020.

###### Sample characteristics and RT-PCR results for SARS-CoV-2 in breast milk

  Author                 N       Maternal                 Delivery                                                      Neonate                 Breast milk                                                                                                                                                                         
  ---------------------- ------- ------------------------ ------------------------------------------------------------- ----------------------- ------------- ------------------------ ------------------ -------- ---------------------------- ------ -------------------------------------- ------------------------------------- ----------
  Chen, 2020 ^[@B8]^     1 -6    Minimum 26, maximum 34   Fever (6/6), cough (2/6), dyspnea (1/6), and diarrhea (1/6)   Evidence of pneumonia   Survived      Minimum 36, maximum 39   Cesarean section   ?        Minimum 1880, maximum 3730   No     Negative (URT and placental tissues)   DO                                    Negative
  Dong, 2020 ^[@B9]^     7       29                       Fever, nasal congestion, and shortness of breath              Evidence of pneumonia   Survived      34                       Cesarean section   Female   3120                         No     Negative (URT)                         Day 6 after delivery                  Negative
  Fan, 2020 ^[@B10]^     8       34                       Fever and nasal congestion                                    Evidence of pneumonia   Survived      37                       Cesarean section   Female   3400                         No     Negative (URT and placental tissues)   DO                                    Negative
                         9       29                       Fever, cough, and nasal congestion                            Evidence of pneumonia   Survived      36                       Cesarean section   Female   2890                         No     Negative (URT and placental tissues)   DO                                    Negative
  Li, 2020 ^[@B11]^      10      30                       Cough and shortness of breath                                 Evidence of pneumonia   Survived      35                       Cesarean section   Male     ?                            No     Negative (URT and placental tissues)   DO                                    Negative
  Liu, 2020 ^[@B12]^     11      34                       Fever                                                         Evidence of pneumonia   Survived      40                       Cesarean section   Male     3250                         MSAF   Negative (URT and placental tissues)   DO and days 1 and 10 after delivery   Negative
                         12      30                       Cough                                                         Evidence of pneumonia   Survived      39                       Vaginal            Male     3670                         No     Negative (URT)                         Day 2 after delivery                  Negative
  Wang, 2020 ^[@B13]^    13      34                       Fever                                                         Evidence of pneumonia   Survived      40                       Cesarean section   Male     3205                         MSAF   Negative (URT and placental tissues)   Days 1 and 3 after delivery           Negative
  Xiong, 2020 ^[@B14]^   14      25                       Fever and cough                                               Evidence of pneumonia   Survived      38                       Vaginal            Male     3070                         No     Negative (URT and placental tissues)   DO                                    Negative
  Liu, 2020 ^[@B15]^     15-24   Minimum 26, maximum 38   Fever (7/10), cough (4/10), and diarrhea (1/10)               Evidence of pneumonia   Survived      Minimum 35, maximum 41   Cesarean section   ?        Minimum 2500, maximum 3670   No     Negative (URT and placental tissues)   DO                                    Negative

URT, Upper Respiratory Tract. MSAF, Meconium Stained Amniotic Fluid.

DO, delivery day or after first lactation.

RESULTS AND DISCUSSION
======================

We found eight studies ([@B8]--[@B15]) analyzing the presence of SARS-CoV-2 RNA in the breast milk of 24 pregnant women with COVID-19 during the third trimester of pregnancy ([Table 1](#tbl01){ref-type="table"}). All patients had fever and/or symptoms of acute respiratory illness and chest computed tomography (CT) images indicative of COVID-19 pneumonia. Most pregnant women had cesarean delivery (91.7%) and two neonates had low birthweight (\< 2,500 g). Biological samples collected immediately after birth from upper respiratory tract (throat or nasopharyngeal) of neonates and placental tissues showed negative results for the presence SARS-CoV-2 by RT-PCR test. In addition, no breast milk samples were positive for SARS-CoV-2. In three studies ([@B10],[@B12],[@B13]) there was a clear recommendation for mother's to not breastfeed their children despite the lack of evidence on the potential viral transmission via breast milk.

As the coronavirus pandemic takes hold, pregnant women infected with SARS-CoV-2 experience fear and uncertainties regarding the care of their child. Making decisions without a robust evidence base may influence mother-child interactions and lead to poor outcomes. Furthermore, there is a lack of consensus among health agencies regarding breastfeeding for women with COVID-19. In February 2020, the National Health Commission of China recommended that neonates of pregnant women with suspected or confirmed COVID-19 should be isolated in a designated unit for at least 14 days and should not be breastfeed due to the high risk of infection ([@B16]). Although this expert working group has suggested breastfeeding only in cases of negative tests for SARS-CoV-2, this warning may contribute to reducing breastfeeding by women with no exposure to the virus which may lead to infant poor health outcomes. On the other hand, interim guidance provided by the Centers for Disease Control and Prevention (CDC) ([@B17]) and the World Health Organization (WHO) ([@B18]) advises that breastfeeding should be determined by the mother in coordination with her family and healthcare providers, and all possible prevention measures to avoid spreading the virus to the infant must be taken including wearing a mask and washing hands and breasts with soap and water before breastfeeding. If the woman opts to express breast milk, all recommendations for cleaning the breast pumps and utensils after each use must be rigorously followed. Consideration should be given to the possibility of someone healthy providing breast milk to the infant using a cup or spoon. This person must receive training from a qualified professional before starting procedures. If there is no production of breast milk by the mother, a human milk bank should be contacted. There are no restrictions on the use of milk from a human breast milk bank ([@B19],[@B20]). The possibility of drug excretion into breast milk with potential adverse effects in breastfeed neonates should also be analyzed ([@B21]). To date, there is no evidence on the presence of SARS-CoV-2 in breast milk of pregnant women with COVID-19. Data provided on current literature are still limited and breastfeeding of women with COVID-19 remains a controversial issue. Further studies with large samples are needed to confirm these results particularly given the importance of breastfeeding in preventing other childhood illnesses.
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